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Background. The RTS,S/AS01E malaria candidate vaccine is being developed for immunization of African
infants through the Expanded Program of Immunization (EPI).
Methods. This phase 2, randomized, open, controlled trial conducted in Ghana, Tanzania, and Gabon evaluated
the safety and immunogenicity of RTS,S/AS01E when coadministered with EPI vaccines. Five hundred eleven infants
were randomized to receive RTS,S/AS01E at 0, 1, and 2 months (in 3 doses with diphtheria, tetanus, and whole-
cell pertussis conjugate [DTPw]; hepatitis B [HepB]; Haemophilus influenzae type b [Hib]; and oral polio vaccine
[OPV]), RTS,S/AS01E at 0, 1, and 7 months (2 doses with DTPwHepB/Hib+OPV and 1 dose with measles and
yellow fever), or EPI vaccines only.
Results. The occurrences of serious adverse events were balanced across groups; none were vaccine-related.
One child from the control group died. Mild to moderate fever and diaper dermatitis occurred more frequently
in the RTS,S/AS01E coadministration groups. RTS,S/AS01E generated high anti–circumsporozoite protein and anti–
hepatitis B surface antigen antibody levels. Regarding EPI vaccine responses upon coadministration when consid-
ering both immunization schedules, despite a tendency toward lower geometric mean titers to some EPI antigens,
predefined noninferiority criteria were met for all EPI antigens except for polio 3 when EPI vaccines were given
with RTS,S/AS01E at 0, 1, and 2 months. However, when antibody levels at screening were taken into account,
the rates of response to polio 3 antigens were comparable between groups.
Conclusion. RTS,S/AS01E integrated in the EPI showed a favorable safety and immunogenicity evaluation.
Trial registration. ClinicalTrials.gov identifier: NCT00436007. GlaxoSmithKline study ID number: 106369
(Malaria-050).
The development of a malaria vaccine has been iden-
tified as a key component of future integrated malaria
control programs and an important step toward sus-
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tainable elimination of malaria in Africa. Improved con-
trol of malaria would have significant benefits in health
and for the economy of sub-Saharan Africa [1–7].
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The RTS,S/AS01 vaccine is being developed for the routine
immunization of infants and children living in areas where
malaria is endemic as part of the Expanded Program of Im-
munization (EPI). The vaccine antigen RTS,S consists of se-
quences of the Plasmodium falciparum circumsporozoite (CS)
protein and the hepatitis B surface antigen (HBsAg). The
GlaxoSmithKline proprietary adjuvant system AS01 contains
the MPL and QS21 immunostimulants and liposomes. Past
trials of RTS,S have been conducted with the closely related
adjuvant system AS02, which contains the same immunostimu-
lants MPL and QS21 and an oil-in-water emulsion.
Phase 2 trials of RTS,S/AS02 have demonstrated a favorable
safety profile in infants when the vaccine was given separately
or in coadministration with EPI vaccines [8, 9]. Noninferiority
of antibody responses against coadministered diphtheria, tet-
anus, pertussis, and Haemophilus influenzae type b (Hib) vac-
cines has been demonstrated [9]. RTS,S/AS02 induced 65%
protection against P. falciparum infection over 6 months when
coadministered with EPI vaccines, despite lower anti-CS titers
than those induced when administration was staggered 2 weeks
apart from the administration of EPI vaccines.
Both in adults and subsequently in children, the RTS,S/AS01
formulation showed improved efficacy and immunogenicity
and an equally favorable safety profile as compared with RTS,S/
AS02, which supports the selection of RTS,S/AS01 for further
development for children and infants [10–12]. RTS,S/AS01E is
the pediatric formulation of RTS,S/AS01. In subjects aged 5–
17 months, the measured vaccine efficacy of RTS,S/AS01E
against clinical malaria was 53%, over a mean 8-month follow-
up period [13].
The delivery of a new malaria vaccine through the EPI would
be the most effective means of achieving rapid high coverage.
We studied the safety and immunogenicity of RTS,S/AS01E ad-
ministered to infants aged 6–10 weeks at the time of the first
administration, when coadministered with the diphtheria, tet-
anus, and whole-cell pertussis conjugate (DTPw) vaccine, hep-
atitis B (HepB) vaccine, Hib vaccine, oral polio vaccine (OPV),
measles vaccine, and yellow fever vaccine routinely used in the
EPI in sub-Saharan Africa. Two RTS,S/AS01E regimens (vac-
cination at 0, 1, and 2 months and vaccination at 0, 1, and 7
months) were studied; both constitute alternative options for
integration into the EPI.
METHODS
Study design. The study was a phase 2, randomized, con-
trolled, open study and was prospectively registered at
ClinicalTrials.gov. Approval was obtained from the Ifakara
Health Research and Development Centre and the National
Review Committee of the National Institution for Medical Re-
search in Tanzania, the Comite´ d’Ethique Re´gional Inde´pendant
de Lambare´ne´ in Gabon, the Kintampo Health Research Center
Scientific Review Committee/Institutional Ethics Committee
and the Ghana Health Service National Ethical Review Com-
mittee in Ghana, the London School of Hygiene and Tropical
Medicine Ethics Committee in the United Kingdom, the Swiss
Tropical Institute Committee in Switzerland, and the Western
Institutional Review Board in the United States.
The independent data monitoring committee appointed to
oversee the RTS,S pediatric development program reviewed the
ethical, quality, and safety aspects of the study conduct. The
study was conducted in accordance with the Helsinki Decla-
ration of 1964 (revised in 1996) and according to Good Clinical
Practice guidelines.
GlaxoSmithKline Biologicals was the study sponsor. The Pro-
gram for Appropriate Technology in Health Malaria Vaccine
Initiative cofunded this trial and was involved in all aspects of
the study design.
Study research centers. The study was conducted at 3 clin-
ical research centers: Kintampo Health Research Center, Kin-
tampo, Ghana; Ifakara Health Research and Development Cen-
tre, Bagamoyo Research and Training Centre, Bagamoyo,
Tanzania; and the Albert Schweitzer Hospital, Medical Research
Unit Lambare´ne´, Lambare´ne´, Gabon. The intensity of malaria
transmission in all 3 study sites is intense and perennial [11,
14–17].
Study participants. For the recruitment of study partici-
pants, lists of potentially eligible infants were generated follow-
ing community-based information programs in the Bagamoyo
and Lambare´ne´ study areas. In Kintampo, the monitoring of
births as part of the research center’s demographic surveillance
system was used. Healthy male and female infants aged 6–10
weeks at the time of the first vaccine dose who had received 1
previous dose of OPV and bacille Calmette-Gue´rin (BCG) were
eligible for enrollment. Written informed consent was obtained
from each child’s parent or guardian before study procedures
were initiated. For nonliterate parents, consent was docu-
mented using a thumbprint and a signature by a literate witness.
Randomization and vaccination. Eligible subjects were
randomized (1:1:1) to 1 of 3 groups (Table 1). The RTS,S/
AS01E (0, 1, 2) group received RTS,S/AS01E at 0, 1, and 2
months—3 doses in coadministration with DTPwHepB/
Hib+OPV. The RTS,S/AS01E (0, 1, 7) group received RTS,S/
AS01E at 0, 1, and 7 months—doses 1 and 2 in coadministra-
tion with DTPwHepB/Hib+OPV and dose 3 in coadministra-
tion with measles and yellow fever vaccines. The control group
received EPI vaccines only. Yellow fever vaccine was not ad-
ministered to infants from Tanzania because it is not included
in the EPI vaccination schedule in Tanzania.
Study vaccines. RTS,S/AS01E, DTPwHepB/Hib (Tritanrix
HepB and Hiberix; GlaxoSmithKline Biologicals), measles vac-
cine (Rouvax; Aventis Pasteur; some subjects from Gabon re-
ceived the local EPI measles vaccine from the Serum Institute
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Table 1. Outline of Study Design to Test Safety and Immunogenicity of RTS,S/AS01E Malaria Candidate Vaccine Integrated
in the Expanded Program of Immunization
Study group,
vaccinations received and blood sampling plan
Study month
1 (screening) 0 1 2 3 4 5 6 7 8
Control ( )Np 171
Vaccines
DTPwHepB/Hib+OPV X X X
Measles, yellow fevera X
Antibody level determination
CS, HBsAg X X X X
BPT X X
DTPw, Hib, polio Xb X
Measles, yellow fevera X X
Blood sample tested for safety X Xc X X
RTS,S/AS01E (0, 1, 2) ( )Np 170
Vaccines
RTS,S/AS01E X X X
DTPwHepB/Hib+OPV X X X
Measles, yellow fevera X
Antibody level determination
CS, HBsAg X X X X
BPT X X
DTPw, Hib, polio Xb X
Measles, yellow fevera
Blood sample tested for safety X Xc X
RTS,S/AS01E (0, 1, 7) ( )Np 170
Vaccines
RTS,S/AS01E X X X
DTPwHepB/Hib+OPV X X X
Measles, yellow fevera X
Antibody level determination
CS, HBsAg X X X X
BPT X X
DTPw, Hib, polio Xb X
Measles, yellow fevera X X
Blood sample tested for safety X Xc X
NOTE. BPT, Bordetella pertussis toxin; CS, circumsporozoite protein of Plasmodium falciparum; DTPw, diphtheria, tetanus, and pertussis
(whole cell) conjugate; HBsAg, hepatitis B surface antigen; HepB, hepatitis B; Hib, Haemophilus influenzae type b; OPV, oral polio vaccine.
a Excluding infants from Tanzania.
b As part of a post hoc analysis, anti-polio antibodies were measured at screening.
c Safety blood samples were evaluated at day 6 after the first vaccine dose.
of India Limited), and yellow fever vaccine (Stamaril; Aventis
Pasteur) were administered intramuscularly. OPV (Polio Sabin;
GlaxoSmithKline Biologicals) was administered orally. Vacci-
nees were observed for 60 min after each vaccination.
Assessment of reactogenicity and safety. Solicited reacto-
genicity data on adverse events (AEs; pain, swelling, drowsiness,
fever, irritability, and loss of appetite) were collected for 7 d
following each dose, and reports of unsolicited nonserious AEs
were collected for 30 d following each dose. Grade 3 (severe)
events were defined as follows: pain that caused the infant to
cry when the limb was moved and/or was spontaneous, swelling
of 120 mm in diameter, fever with an axillary temperature of
37.5C (especially of 139C), irritability (crying that could
not be comforted) that prevented normal activity, drowsiness
that prevented normal activity, and loss of appetite (not eating
at all).
Serious AEs (SAEs) were recorded throughout the study pe-
riod (months 0–8). All seizures occurring within 30 d after
vaccination were reported as SAEs, and those occurring within
7 d were reported according to the Brighton Collaboration
guidelines [18].
Time points for the measurement of levels hematological
function (hemoglobin, platelets, and white blood cells), renal
function (creatinine), and hepatic function (alanine amino-
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transferase) are detailed in Table 1. Clinically significant ab-
normal laboratory findings were reported as AEs or SAEs.
Grade 3 abnormalities were predefined as follows: hemoglobin
level, !5.0 g/dL; total white blood cell count, ! cells/31.4 10
mL; platelet count, ! cells/mL; alanine aminotransferase325 10
level, 15.1 times the upper limit of the reference range; cre-
atinine level, 13.1 times the upper limit of the reference range.
Assessment of immunogenicity. Time points for measure-
ment of levels of antibodies against CS, HBsAg, diphtheria
toxin, tetanus toxin, polyribosyl ribitol phosphate (PRP) for
Hib, Bordetella pertussis toxin (BPT), polio 1, polio 2, polio 3,
measles, and yellow fever antigens are detailed in Table 1.
The levels of immunoglobulin G antibodies to CS were mea-
sured by a R32LR antigen-based enzyme-linked immunosor-
bent assay (ELISA) with a detection cutoff of 0.5 EU/mL, as
described elsewhere [19]. Antibody levels were measured using
an in-house ELISA for anti-HBsAg (seroprotective cutoff, 10
mIU/mL) [12], anti-diphtheria (seroprotective cutoff, 0.1 IU/
mL), anti-PRP (Hib; seroprotective cutoff, 0.15 mg/mL), and
anti-tetanus (seroprotective cutoff, 0.1 IU/mL). Antibody levels
were measured for anti-BPT by use of a commercial immu-
noglobulin G ELISA (Anilabsystems; seropositivity cutoff, 115
EI.U/mL), for anti-measles immunoglobulin G by use of a com-
mercial ELISA (Enzygnost; Dade Behring; seroconversion cut-
off, 150 mIU/mL), for titers of anti–polio 1, anti–polio 2, and
anti–polio 3 by use of a standard poliovirus microneutralization
assay (median effective dose protective serum dilution factor,
8), and for anti–yellow fever by use of a yellow fever plaque
reduction neutralization test (protective serum dilution fac-
tor, 10).
Statistical methods. Statistical analyses were conducted
using SAS (version 8; SAS Institute). The trial sample size was
calculated to give 90% power to detect a 2.5-fold difference (2-
sided; 5% significance) in the rate of a SAE occurring with a
frequency of 10% in the control group compared to each of
the experimental regimens. For secondary immunogenicity
endpoints, the trial had 195% power to demonstrate nonin-
feriority for all antigens except measles antigen, for which
power was 82%, based on historical response rates.
Safety was analyzed on the total vaccinated cohort, which
included all subjects with at least 1 documented study vaccine
administration. The primary endpoint was the occurrence of
SAEs from months 0–8. The proportion of subjects with a SAE,
as classified by the preferred term in the Medical Dictionary
for Regulatory Activities (MedDRA), was tabulated with exact
95% confidence intervals (CIs). Summaries were tabulated for
the incidence, intensity, and relationship of solicited symptoms
and unsolicited AEs, as classified by MedDRA preferred terms.
According to protocol, all solicited local injection site symptoms
were considered to be causally related to vaccination. Frequency
distributions of biochemical and hematological parameters by
severity grades were tabulated.
The primary analysis of immunogenicity was performed on
the According to Protocol cohort, which included subjects who
met all eligibility criteria, complied with the study procedures,
and had no elimination criteria. Seropositivity, seroprotection,
or seroconversion rates were defined with 95% CIs. Antibody
titers were summarized by geometric mean titers (GMTs) with
95% CIs for all antigens.
For the analysis of noninferiority, the differences in anti-
HBsAg, anti-diphtheria, anti-tetanus, anti-PRP, anti–polio 1,
anti–polio 2, and anti–polio 3 seroprotection rates at month 3
and those in anti-measles and anti–yellow fever seroconversion
rates at month 8 between the control group and RTS,S/AS01E
groups were calculated with 95% CIs (standardized asymptotic)
around this difference. If the upper limit of the 2-sided 95%
CI was !10%, then the noninferiority of the RTS,S/AS01E
groups compared with the control group was considered to be
demonstrated. For anti-BPT, for which there is no demon-
strated correlate of protection, the 95% CI (analysis of variance
model; pooled variance) on the GMT ratio (GMT of the control
group divided by that of the RTS,S/AS01E group) was calculated.
If the upper limit of this 95% CI was !1.5, then the nonin-
feriority of the RTS,S/AS01E groups compared with the control
group was considered to be demonstrated. As a post hoc anal-
ysis, polio vaccine responses were investigated when taking into
account polio antibody titers at screening. A polio vaccine re-
sponse was defined as the appearance of antibodies at month
3 (titer, 8 EU/mL) in initially seronegative subjects or a 2-
fold increase in postvaccination antibody titers over prevacci-
nation titers in initially seropositive subjects.
RESULTS
Subject cohort. Figure 1 summarizes subject participation
during the course of the study. Age, sex, and weight were bal-
anced between groups. The mean age of subjects at baseline
was 7.0 weeks (standard deviation, 1.0 weeks), the mean weight
at baseline was 4.9 kg (standard deviation, 0.6 kg), and 51%
of the subjects were male. All participants had received a first
dose of OPV and BCG vaccine in the neonatal period.
Safety outcome primary endpoint. From the time of the
first vaccination until month 8, the proportion of subjects with
a SAE was similar in all groups: 22.9% in the RTS,S/AS01E (0,
1, 2) group, 18.2% in the RTS,S/AS01E (0, 1, 7) group, and
21.1% in the control group (Table 2). No SAE occurred with
a clinically concerning higher incidence in either RTS,S/AS01E
groups compared with the control group.
No seizures occurred within 7 d after vaccination. Three
seizures were reported within 30 d after vaccination, 2 in sub-
jects from the RTS,S/AS01E (0, 1, 7) group and 1 in a subject
from the control group.
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Figure 1. Summary of subject participation in a phase 2, randomized, open, controlled trial conducted in Ghana, Tanzania, and Gabon to evaluate
the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine coadministered with Expanded Program of Immunization vaccines.
Subjects in the RTS,S/AS01E (0, 1, 2) group were vaccinated with RTS,S/AS01E and DTPwHepB/Hib+OPV (diphtheria, tetanus, and whole-cell pertussis
conjugate; hepatitis B; Haemophilus influenzae type b; and oral polio vaccine) at vaccine visits 1, 2, and 3 (doses 1, 2, and 3) and with measles and
yellow fever vaccines at vaccine visit 4 (dose 4). Subjects in the RTS,S/AS01E (0, 1, 7) group were vaccinated with RTS,S/AS01E and DTPwHepB/
Hib+OPV at vaccine visits 1 and 2 (doses 1 and 2), with DTPwHepB/Hib+OPV at vaccine visit 3 (dose 3), and with RTS,S/AS01E and measles and
yellow fever vaccines at vaccine visit 4 (dose 4). Subjects in the control group were vaccinated with DTPwHepB/Hib+OPV at vaccine visits 1, 2, and
3 (doses 1, 2, and 3) and with measles and yellow fever vaccines at vaccine visit 4 (dose 4).
No SAE was considered by the investigator to be related to
vaccination. One study participant in the control group died
because of pneumonia and severe P. falciparum malaria with
severe anemia.
Solicited AEs. The occurrence of solicited events following
vaccination is summarized in Table 3. No local solicited injec-
tion site pain of grade 3 occurred. Grade 3 swelling was rare,
occurring after 0.6% of doses of any vaccine in each study
group.
Fever was reported more frequently in participants who re-
ceived RTS,S/AS01E in combination with DTPwHepB/Hib+OPV
compared with participants who received DTPwHepB/Hib+OPV
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Table 2. Occurrence of Unsolicited Adverse Events in the Total Vaccinated Cohort
MedDRA preferred term
RTS,S/AS01E (0, 1, 2) group
( )Np 170
RTS,S/AS01E (0, 1, 7) group
( )Np 170
Control group
( )Np 171
No. of
subjectsa % (95% CI)
No. of
subjectsa % (95% CI)
No. of
subjectsa % (95% CI)
Serious adverse events occurring in 12% of subjects
in any vaccine group (whole follow-up)
At least 1 serious adverse event 39 22.9 (16.9–30.0) 31 18.2 (12.7–24.9) 36 21.1 (15.2–27.9)
Anemia 6 3.5 (1.3–7.5) 10 5.9 (2.9–10.6) 14 8.2 (4.5–13.4)
Febrile convulsion 1 0.6 (0.0–3.2) 4 2.4 (0.6–5.9) 0 0.0 (0.0–2.1)
Gastroenteritis 19 11.2 (6.9–16.9) 11 6.5 (3.3–11.3) 14 8.2 (4.5–13.4)
Impetigo 3 1.8 (0.4–5.1) 1 0.6 (0.0–3.2) 4 2.3 (0.6–5.9)
Plasmodium falciparum
infection
5 2.9 (1.0–6.7) 10 5.9 (2.9–10.6) 16 9.4 (5.4–14.7)
Pneumonia 11 6.5 (3.3–11.3) 10 5.9 (2.9–10.6) 10 5.8 (2.8–10.5)
Sepsis 2 1.2 (0.1–4.2) 2 1.2 (0.1–4.2) 4 2.3 (0.6–5.9)
Upper respiratory tract infection 4 2.4 (0.6–5.9) 5 2.9 (1.0–6.7) 6 3.5 (1.3–7.5)
Nonserious adverse events occurring in 15% of subjects
in any vaccine group (30 days after vaccination)
At least 1 adverse event 160 94.1 (89.4–97.1) 161 94.7 (90.2–97.6) 164 95.9 (91.7–98.3)
Anemia 11 6.5 (3.3–11.3) 19 11.2 (6.9–16.9) 11 6.4 (3.3–11.2)
Bronchitis 17 10.0 (5.9–15.5) 17 10.0 (5.9–15.5) 21 12.3 (7.8–18.2)
Conjunctivitis 16 9.4 (5.5–14.8) 21 12.4 (7.8–18.3) 19 11.1 (6.8–11.2)
Cough 21 12.4 (7.8–18.3) 30 17.6 (12.2–24.2) 24 14.0 (9.2–20.2)
Dermatitis diaper 8 4.7 (2.1–9.1) 9 5.3 (2.–9.8) 0 0.0 (0.0–2.1)
Diarrhoea 21 12.4 (7.8–18.3) 24 14.1 (9.3–20.3) 24 14.0 (9.2–20.2)
Enteritis 8 4.7 (2.1–9.1) 12 7.1 (3.7–12.0) 16 9.4 (5.4–14.7)
Gastroenteritis 29 17.1 (11.7–23.6) 25 14.7 (9.7–20.9) 32 18.7 (13.2–25.4)
Impetigo 7 4.1 (1.7–8.3) 4 2.4 (0.6–5.9) 14 8.2 (4.5–13.4)
Induration 26 15.3 (10.2–21.6) 28 16.5 (11.2–22.9) 29 17.0 (11.7–23.4)
Nasopharyngitis 53 31.2 (24.3–38.7) 62 36.5 (29.2–44.2) 71 41.5 (34.0–49.3)
Otitis media 10 5.9 (2.9–10.6) 8 4.7 (2.1–9.1) 8 4.7 (2.0–9.0)
P. falciparum infection 9 5.3 (2.4–9.8) 11 6.5 (3.3–11.3) 14 8.2 (4.5–13.4)
Pneumonia 19 11.2 (6.9–16.9) 11 6.5 (3.3–11.3) 9 5.3 (2.4–9.8)
Rhinitis 16 9.4 (5.5–14.8) 21 12.4 (7.8–18.3) 21 12.3 (7.8–18.2)
Rhinorrhoea 19 11.2 (6.9–16.9) 19 11.2 (6.9–16.9) 23 13.5 (8.7–19.5)
Skin infection 6 3.5 (1.3–7.5) 8 4.7 (2.1–9.1) 13 7.6 (4.1–12.6)
Staphylococcal skin infection 4 2.4 (0.6–5.9) 10 5.9 (2.9–10.6) 5 2.9 (1.0–6.7)
Upper respiratory tract infection 66 38.8 (31.5–46.6) 66 38.8 (31.5–46.6) 65 38.0 (30.7–45.7)
NOTE. Subjects who received at least 1 vaccine dose were included in the analysis. CI, confidence interval (exact); MedDRA, Medical Dictionary
for Regulatory Activities.
a Number of subjects for whom the symptom was reported at least once.
alone and in participants who received RTS,S/AS01E in combi-
nation with measles and yellow fever vaccines compared with
participants who received measles and yellow fever vaccines
alone. Grade 3 fever was rare and balanced across vaccine groups.
No grade 3 drowsiness or loss of appetite was reported.
Unsolicited AEs. Unsolicited AEs were reported in similar
proportions of subjects in the RTS,S/AS01E (0, 1, 2), RTS,S/
AS01E (0, 1, 7), and control groups (94.1%, 94.7%, and 95.9%,
respectively) (Table 2). Nasopharyngitis and upper respiratory
tract infection were the most frequently reported unsolicited
symptoms, occurring with a similar incidence in all study
groups. Diaper dermatitis occurred more frequently in RTS,S/
AS01E recipients than in control participants (8 subjects in the
RTS,S/AS01E [0, 1, 2] group, 9 subjects in the RTS,S/AS01E [0,
1, 7] group, and 0 subjects in the control group).
Unsolicited AEs with a causal relationship to vaccination
were reported with similar frequencies in all study groups
(17.1% in the RTS,S/AS01E [0, 1, 2] group, 18.2% in the RTS,S/
AS01E [0, 1, 7] group, and 19.9% in the control group), pre-
dominantly because of reports of induration from 1 study cen-
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Figure 2. Geometric mean titers (GMTs) at months 0, 2, 3, 7, and 8 of antibodies to Plasmodium falciparum circumsporozoite (CS) protein in subjects
who received the RTS,S/AS01E malaria candidate vaccine and control subjects. Subjects in the RTS,S/AS01E (0, 1, 2) group received RTS,S/AS01E at
study months 0, 1, and 2; subjects in the RTS,S/AS01E (0, 1, 7) group received RTS,S/AS01E at study months 0, 1, and 7; and subjects in the control
group did not receive RTS,S/AS01E. Error bars show 95% confidence intervals (CIs). *GMTs 1 month after dose 2 (month 2) in the RTS,S/AS01E (0,
1, 7) group are extrapolated from the RTS,S/AS01E (0, 1, 2) group.
ter (15.3% in the RTS,S/AS01E [0, 1, 2] group, 16.5% in the
RTS,S/AS01E [0, 1, 7] group, and 17.0% in the control group).
Other unsolicited AEs considered to be causally related to vac-
cination were as follows: injection site induration in 2 subjects,
vomiting in 1 subject, and injection site cellulitis in 1 subject
in the RTS,S/AS01E (0, 1, 2) group; injection site induration in
4 subjects in the RTS,S/AS01E (0, 1, 7) group; and injection
site induration in 4 subjects and cough in 1 subject in the
control group. With the exception of the subject who died, no
subject withdrew from the study as a result of an AE.
Laboratory safety monitoring. Of the few hematological
and biochemical values outside the reference range, 2 values
were grade 3 in severity; both occurred in subjects from the
control group. One subject had a low hemoglobin concentra-
tion (4.1 g/dL) at month 8; no follow-up laboratory safety data
were available for this subject, who was reported to have severe
sickle cell disease, severe pediatric immune deficiency syn-
drome, and severe sepsis at the month 7 visit. One subject had
an increased level of alanine aminotransferase (444 IU/L) 6 d
after dose 1; alanine aminotransferase levels were within the
reference range at month 3 and month 8 (25.0 IU/L and 12.6
IU/L, respectively).
Immunogenicity results. Across vaccine groups, 26%–30%
of subjects had detectable anti-CS antibodies, at low titers, prior
to RTS,S/AS01E vaccination. At month 3, 99% of subjects in
both the RTS,S/AS01E (0, 1, 2) and RTS,S/AS01E (0, 1, 7) groups
had detectable anti-CS antibodies, compared with a low pro-
portion of anti-CS seropositivity in the control group (11% of
subjects). The highest anti-CS GMT of 190.3 EU/mL was ob-
served 1 month after dose 3 (month 3) in the RTS,S/AS01E (0,
1, 2) group, which compares with a GMT of 107.8 EU/mL 1
month after the third dose (month 8) in the RTS,S/AS01E (0,
1, 7) group (Figure 2).
Prevaccination anti-HBsAg GMTs were low and similar
across vaccine groups (9–13 mIU/mL). At month 3, 100% of
subjects in both RTS,S/AS01E groups and 98% of subjects in
the control group had protective levels of anti-HBsAg anti-
bodies (Table 4). The highest GMT (59,814 mIU/mL) was ob-
served at month 8 in the RTS,S/AS01E (0, 1, 7) group, compared
with a GMT of 1356 mIU/mL at month 3 in the RTS,S/AS01E
(0, 1, 2) group and of 338 mIU/mL in the control group.
Noninferiority of anti-HBsAg, anti-diphtheria, anti-tetanus,
anti-PRP, anti–polio 1, anti–polio 2, and anti–polio 3 seropro-
tection rates and anti-BPT antibody titers was demonstrated
for the RTS,S/AS01E (0, 1, 2) and (0, 1, 7) groups, compared
with the control group, with the exception of anti–polio 3 in
the RTS,S/AS01E (0, 1, 2) group (Table 4). Noninferiority of
anti-measles and anti–yellow fever seroconversion rates was
demonstrated for RTS,S/AS01E coadministered with measles
and yellow fever vaccines compared with measles and yellow
fever vaccines given alone.
Seroprotective and seropositive antibody titers were similar
and high for anti-HBsAg, anti-diphtheria, anti-tetanus, anti-
PRP, anti-BPT, and anti–polio (serotypes 1 and 2) (Table 4).
Seroprotection rates for anti–polio 3 were slightly lower in
participants of the RTS,S/AS01E (0, 1, 2) group (86.7% of sub-
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Table 4. Responses to Antigens from the Expanded Program of Immunization—According to Protocol Cohort for Immunogenicity
Study group,
month of assessment, antigen
Rate
measured
Noninferiority assessment
No. (%) of subjectsa GMT, mIU/mL (95% CI)
RTS,S/AS01E Control
Difference,
% (95% CI)b RTS,S/AS01E Control
RTS,S/AS01E (0, 1, 2), month 3
HBsAg SP 130 (100) 126 (97.6) 2.38 (6.78 to 0.54) 1356 (1101–1670) 338 (266–429)
Diphtheria SP 142 (96.5) 142 (100) 3.52 (0.83–7.99) 1.0 (0.9–1.2) 1.4 (1.2–1.7)
Tetanus SP 142 (100) 142 (100) 0.00 (2.64 to 2.64) 2.8 (2.3–3.3) 3.7 (3.2–4.3)
Hib PRP SP 141 (99.3) 142 (98.6) 0.70 (4.37 to 2.63) 13.3 (10.6–16.7) 19.0 (15.2–23.6)
Polio 1 SP 136 (94.9) 131 (94.7) 0.20 (6.14 to 5.63) 464 (343–627) 500 (365–685)
Polio 2 SP 135 (98.5) 131 (99.2) 0.72 (2.86 to 4.57) 494 (390–626) 407 (329–503)
Polio 3 SP 135 (86.7) 133 (95.5) 8.82 (2.11–16.16) 124 (92–166) 205 (157–269)
BPT S+ 139 (85.3)c 139 (106.5)c 0.80 (0.69–0.93)d … …
RTS,S/AS01E (0, 1, 7), month 3
HBsAg SP 119 (100) 126 (97.6) 2.38 (6.78 to 0.80) 651 (541–784) 338 (266–429)
Diphtheria SP 133 (97.0) 142 (100) 3.01 (0.32–7.49) 1.1 (0.9–1.3) 1.4 (1.2–1.7)
Tetanus SP 133 (100) 142 (100) 0.00 (2.64 to 2.82) 2.6 (2.2–3.1) 3.7 (3.2–4.3)
Hib PRP SP 132 (100) 142 (98.6) 1.41 (5.00 to 1.45) 15.6 (12.6–19.4) 19.0 (15.2–23.6)
Polio 1 SP 125 (94.4) 131 (94.7) 0.26 (5.79 to 6.46) 486 (343–688) 500 (365–685)
Polio 2 SP 124 (100) 131 (99.2) 0.76 (4.21 to 2.26) 563 (457–694) 407 (329–503)
Polio 3 SP 125 (92.8) 133 (95.5) 2.69 (3.30 to 9.19) 149 (112–197) 205 (157–269)
BPT S+ 131 (104.4)c 139 (106.5)c 0.98 (0.85–1.13)d … …
RTS,S/AS01E (0, 1, 7), month 8
Measles SC 109 (91.7) 117 (88.9) 2.85 (10.95 to 5.23) 1287 (1029–1608) 1267 (1007–1594)
Yellow fever SC 35 (97.1) 35 (94.3) 2.86 (16.30 to 9.67) 203 (134–307) 179 (114–279)
NOTE. Subjects with available postvaccination results were included in the analysis. BPT, Bordetella pertussis toxin; CI, confidence interval; GMT, geometric
mean titer; HBsAg, hepatitis B surface antigen; Hib, Haemophilus influenzae type b; PRP, polyribosyl ribitol phosphate; S+, seropositive rate (percentage of
subjects with antibody titers above the seropositive cutoff); SC, seroconversion rate (percentage of initially seronegative subjects who were seropositive after
vaccination); SP, seroprotective rate (percentage of subjects with antibody titers above the seroprotective cutoff).
a No. (%) of subjects, unless otherwise indicated.
b Difference between the percentage of the control group and that of the RTS,S/AS01E group, unless otherwise indicated.
c No. of subjects (GMT).
d Ratio of the GMT of the control group to that of the RTS,S/AS01E group.
jects). Seropositive levels for anti-measles and anti–yellow fever
were similar across vaccine groups.
A post hoc analysis of anti-polio responses was conducted
to further explore the observed differences in anti–polio 3 re-
sponses induced by OPV in coadministration with RTS,S/AS01E
compared with administration of OPV without RTS,S/AS01E.
A heterogeneity across vaccine groups of anti–polio 3 titers,
but not anti–polio 1 or anti–polio 2 titers (data not shown),
was found at screening whereby a higher proportion of sero-
negative subjects was observed in the RTS,S/AS01E (0, 1, 2) and
RTS,S/AS01E (0, 1, 7) groups compared with the control group
( and , respectively; Fisher exact test). AnPp .015 Pp .049
analysis of polio 3 antibody responses that took into account
titers at screening revealed equivalent vaccine responses across
the 3 groups (Table 5).
At month 3, GMTs for anti-diphtheria, anti-tetanus, anti-
PRP, anti-BPT, and anti–polio 3 serotypes tended to be lower
in the RTS,S/AS01E coadministration groups than in the control
group. This effect was more marked when all 3 doses were
given in coadministration (RTS,S/AS01E [0, 1, 2] group) rather
than when 2 doses were coadministered (RTS,S/AS01E [0, 1, 7]
group).
DISCUSSION
This is the first study of the RTS,S/AS01E malaria candidate
vaccine integrated into the EPI schedule, with vaccinations
starting at 6 weeks of age. Overall, the study showed a favorable
safety assessment of RTS,S/AS01E incorporation into the EPI
schedule, which is in line with previous results in which the
closely related RTS,S/AS02D vaccine was coadministered with
EPI vaccines with a tetravalent DTPw/Hib vaccine in Tanzania
[9]. Mild or moderate fever was reported more frequently in
RTS,S/AS01E coadministered groups than in control groups
with EPI vaccines given alone, but grade 3 fever was rare in
any of the study groups. The occurrence of SAEs during the
whole reporting period and that of unsolicited AEs within 30
d after vaccination were reported in a similar proportion of
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Table 5. Seropositivity rates, Geometric Mean Titers (GMTs), and Vaccine Response for Anti–Polio 3 Antibodies in the
According to Protocol Cohort for Immunogenicity
Study group,
timing or seropositivitystatus at screening No. of subjects % (95% CI) GMT (95% CI)
Vaccine response, %
(95% CI)
Anti–polio 3 antibody responses over time
RTS,S/AS01E (0, 1, 2)
Screening 128 47.7 (38.8–56.7) 14.2 (10.7–18.9) …
Month 3 112 88.4 (81.0–93.7) 130.4 (95.9–177.3) 75.0 (65.9–82.7)
RTS,S/AS01E (0, 1, 7)
Screening 117 50.4 (41.0–59.8) 16.1 (12.0–21.8) …
Month 3 100 93.0 (86.1–97.1) 149.1 (110.3–201.5) 78.0 (68.6–85.7)
Control
Screening 118 63.6 (54.2–72.2) 25.4 (18.4–35.1) …
Month 3 97 94.8 (88.4–98.3) 199.2 (144.6–274.5) 73.2 (63.2–81.7)
Anti–polio 3 antibody responses at month 3
according to seropositivity status at screening
RTS,S/AS01E (0, 1, 2)
Seronegative 60 85.0 (73.4–92.9) 94.2 (61.2–145.1) 85.0 (73.4–92.9)
Seropositive 52 92.3 (81.5–97.9) 189.8 (123.7–291.0) 63.5 (49.0–76.4)
RTS,S/AS01E (0, 1, 7)
Seronegative 52 92.3 (81.5–97.9) 120.5 (80.0–181.5) 92.3 (81.5–97.9)
Seropositive 48 93.8 (82.8–98.7) 187.7 (119.5–294.7) 62.5 (47.4–76.0)
Control
Seronegative 36 94.4 (81.3–99.3) 142.2 (84.3–239.8) 94.4 (81.3–99.3)
Seropositive 61 95.1 (86.3–99.0) 243.1 (161.6–365.8) 60.7 (47.3–72.9)
NOTE. Subjects with both prevaccination and postvaccination results were included. Seronegative subjects had an antibody titer of !8 times the
median effective dose (ED50) prior to vaccination. Seropositive subjects had an antibody titer of 8 ED50 prior to vaccination. For initially seronegative
subjects, vaccine response was defined as an antibody titer at month 3 of 8 ED50. For initially seropositive subjects, vaccine response was defined
as an antibody titer at month 3 of 2-fold the prevaccination antibody titer. Similar results were obtained when a 4-fold increase criterion was used
(data not shown). CI, confidence interval; GMT, geometric mean antibody titer.
subjects in each study group; unsolicited AEs related to vac-
cination were predominantly due to reports of induration at 1
study center that were balanced across groups.
This study also assessed the antibody responses to coadmin-
istered EPI antigens. As in a previously reported trial in Tan-
zania [9], GMTs to diphtheria, tetanus, BPT, Hib, and polio 3
antigens were slightly lower in the RTS,S/AS01E coadmini-
stration groups than in the control group, more so when all
3 DTPwHepB/Hib+OPV vaccine doses were coadministered
(RTS,S/AS01E [0, 1, 2] group) than when 2 doses were coad-
ministered (RTS,S/AS01E [0, 1, 7] group). There was no inter-
ference with polio 1, polio 2, measles, and yellow fever re-
sponses upon coadministration. Overall, the seropositivity and
seroprotection rates were high and in accordance with the ex-
pected rates of EPI antigen responses in resource-limited coun-
tries [20–24], and the predefined noninferiority criteria were
met for the DTPwHepB/Hib+OPV, measles, and yellow fever
antigens, except for polio 3 antigen in the RTS,S/AS01E (0, 1,
2) group.
An apparent interaction between an oral live attenuated vac-
cine and a recombinant injected vaccine was unexpected, and
this finding may have been due to chance in the context of the
multiple comparisons that were made. A post hoc analysis of
the screening samples supports the view that the differences in
the response to anti–polio 3 between groups may be related to
a heterogeneity across groups in anti–polio 3 antibody levels
at screening: there was a higher proportion of polio 3 sero-
negative subjects and lower polio 3 GMTs in both RTS,S/AS01E
groups at screening, in comparison with the control group.
When polio type 3 immune responses were analyzed taking
into account antibody levels at screening, as is frequently done
when assessing polio immunization responses in infants [25,
26], similar vaccine response rates were observed in all 3 groups.
Further evaluation of OPV responses are planned as part of
the ongoing phase 3 RTS,S/AS01E clinical trial.
In terms of anti-CS responses, the results of this study con-
firm the induction of high anti-CS antibody responses by
RTS,S/AS01E vaccination; levels were well above the minimal
responses induced by natural parasite exposure. The peak re-
sponse following the third dose in both vaccination schedules
in the study was higher than the peak following 2 doses, which
supports previous results showing the superiority of a 3-dose
schedule compared with a 2-dose schedule [12]. Also in line
with results of a previous study in children aged 5–17 months
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in Ghana [11], this study confirmed that a higher peak anti-
CS response is induced by a schedule of vaccination at 0, 1,
and 2 months compared with a schedule at 0, 1, and 7 months.
The RTS,S antigen is a recombinant construct that also ex-
presses HBsAg. This study shows that RTS,S/AS01E can be in-
corporated into the EPI with another HepB-containing com-
bination vaccine without generating safety concerns. Higher
anti-HBsAg GMTs were found in the RTS,S/AS01E groups com-
pared with those in the control group, which might be asso-
ciated with the induction of longer lasting protection. Unlike
the CS response, the HBsAg response was highest when the
third RTS,S/AS01E dose was delayed—in the schedule of vac-
cination at 0, 1, and 7 months compared with that at 0, 1, and
2 months, as was previously found in a RTS,S schedule study
among slightly older children [11]. This is in line with a well-
described characteristic of hepatitis B vaccination responses:
the immune response to a delayed last immunization is higher
than when it follows the previous doses closely [27, 28].
In summary, this trial has shown a favorable safety and im-
munogenicity evaluation of the RTS,S/AS01E malaria candidate
vaccine introduced into the EPI on a schedule of vaccination
at 0, 1, and 2 months or on a schedule at 0, 1, and 7 months.
Because a schedule at 0, 1, and 2 months can be readily im-
plemented in the EPI and may be associated with higher cov-
erage compared with a schedule at 0, 1, and 7 months, the
schedule at 0, 1, and 2 months has been selected for further
assessment in the ongoing RTS,S/AS01E phase 3 efficacy study.
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